Watch Ticker

HOOKIPA Pharma Inc. Common Stock

Go to HOOKIPA Pharma Inc. Common Stock Website

$0.91

-0.01 (-1.19%)

Live

Previous Close

$0.923

Day Range

$0.9025 - $0.9485

Previous Day Range

$0.8838 - $0.95

Market Cap

$10.8 million USD

Day Vol.

90670

Previous Day Vol.

46993

Currency

USD

Primary Exchange

Nasdaq

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. I...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight

The squamous cell carcinoma (SCC) market is experiencing robust growth due to the increasing incidence of the disease and advancements in treatment options. Over 75 companies are working on 80+ pipeline therapies to improve the SCC treatment landscape.

Related tickers: HOOK, NBTX, GSK, AZN, MRNA, EXEL.

Read Full Article

HOOKIPA Pharma Inc. - HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.

Related tickers: HOOK.

Read Full Article

Trending Tickers

Please sign in to view